Resultados da busca - Matthias Pinter
- Mostrando 1 - 20 resultados de 59
- Ir para a próxima página
-
1
-
2
-
3
-
4
-
5
The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma por Matthias Pinter, Rakesh K. Jain, Dan G. Duda
Publicado em 2020Revisão -
6
-
7
-
8
The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma – a pilot study por Matthias Pinter, Wolfgang Sieghart, Thomas Reiberger, Nataliya Rohr‐Udilova, Arnulf Ferlitsch, Markus Peck‐Radosavljevic
Publicado em 2011Artigo -
9
Sorafenib in Unresectable Hepatocellular Carcinoma from Mild to Advanced Stage Liver Cirrhosis por Matthias Pinter, Wolfgang Sieghart, Ivo Graziadei, Wolfgang Vogel, A Maieron, Robert Königsberg, Adalbert Weißmann, Gabriela Kornek, Christina Plank, Markus Peck‐Radosavljevic
Publicado em 2009Artigo -
10
Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers por Vera Himmelsbach, Matthias Pinter, Bernhard Scheiner, Marino Venerito, Friedrich Sinner, Carolin Zimpel, Jens U. Marquardt, Jörg Trojan, Oliver Waidmann, Fabian Finkelmeier
Publicado em 2022Artigo -
11
Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol por Thomas Reiberger, Gregor Ulbrich, Arnulf Ferlitsch, B.A. Payer, Philipp Schwabl, Matthias Pinter, Birgit Heinisch, Michael Trauner, Ludwig Kramer, Markus Peck‐Radosavljevic
Publicado em 2012Artigo -
12
Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality por Dalila Costa, Benedikt Simbrunner, Mathias Jachs, Lukas Hartl, David Bauer, Rafael Paternostro, Philipp Schwabl, Bernhard Scheiner, Albert Friedrich Stättermayer, Matthias Pinter, Michael Trauner, Mattias Mandorfer, Thomas Reiberger
Publicado em 2020Artigo -
13
Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient por Mathias Jachs, Lukas Hartl, Benedikt Simbrunner, Georg Semmler, Lorenz Balcar, Benedikt Hofer, Michael Schwarz, David Bauer, Albert Friedrich Stättermayer, Matthias Pinter, Michael Trauner, Thomas Reiberger, Mattias Mandorfer
Publicado em 2024Artigo -
14
A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade por Ivy X. Chen, Kathleen Newcomer, Kristen E. Pauken, Vikram R. Juneja, Kamila Naxerova, M. Wu, Matthias Pinter, Debattama R. Sen, Meromit Singer, Arlene H. Sharpe, Rakesh K. Jain
Publicado em 2020Artigo -
15
Study protocol: Fecal Microbiota Transplant combined with Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma who failed to achieve or maintain objective response to... por Katharina Pomej, Adrian Frick, Bernhard Scheiner, Lorenz Balcar, Larissa Pajancic, Anton Klotz, Alexander Kreuter, Katharina Lampichler, Katharina Regnat, Kerstin Zinober, Michael Trauner, Dietmar Tamandl, Christoph Gasché, Matthias Pinter
Publicado em 2025Artigo -
16
Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma por Bernhard Scheiner, Martha M. Kirstein, Sabine Popp, Florian Hucke, Simona Bota, Nataliya Rohr‐Udilova, Thomas Reiberger, Christian Müller, Michael Trauner, Markus Peck‐Radosavljevic, Arndt Vogel, Wolfgang Sieghart, Matthias Pinter
Publicado em 2018Artigo -
17
Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death por Mathias Jachs, Lukas Hartl, Benedikt Simbrunner, David Bauer, Rafael Paternostro, Bernhard Scheiner, Philipp Schwabl, Albert Friedrich Stättermayer, Matthias Pinter, Ernst Eigenbauer, Peter Quehenberger, Michael Trauner, Thomas Reiberger, Mattias Mandorfer
Publicado em 2021Artigo -
18
The Sequential Application of Baveno VII Criteria and VITRO Score Improves Diagnosis of Clinically Significant Portal Hypertension por Mathias Jachs, Lukas Hartl, Benedikt Simbrunner, David Bauer, Rafael Paternostro, Bernhard Scheiner, Lorenz Balcar, Georg Semmler, Albert Friedrich Stättermayer, Matthias Pinter, Peter Quehenberger, Michael Trauner, Thomas Reiberger, Mattias Mandorfer
Publicado em 2022Artigo -
19
Use of inhibitors of the renin–angiotensin system is associated with longer survival in patients with hepatocellular carcinoma por Matthias Pinter, Arndt Weinmann, Marcus‐Alexander Wörns, Florian Hucke, Simona Bota, Jens U. Marquardt, Dan G. Duda, Rakesh K. Jain, Peter R. Galle, Michael Trauner, Markus Peck‐Radosavljevic, Wolfgang Sieghart
Publicado em 2017Artigo -
20
Safety of direct oral anticoagulants in patients with advanced liver disease por Georg Semmler, Katharina Pomej, David Bauer, Lorenz Balcar, Benedikt Simbrunner, Teresa Binter, Lukas Hartl, Jeannette Becker, Matthias Pinter, Peter Quehenberger, Michael Trauner, Mattias Mandorfer, Ton Lisman, Thomas Reiberger, Bernhard Scheiner
Publicado em 2021Artigo
Ferramentas de busca:
Assuntos relacionados
Internal medicine
Medicine
Hepatocellular carcinoma
Gastroenterology
Oncology
Cancer
Immunotherapy
Cirrhosis
Chemotherapy
Adverse effect
Bevacizumab
Cohort
Sorafenib
Atezolizumab
Cancer research
Liver disease
Nivolumab
Portal hypertension
Portal venous pressure
Biology
Confidence interval
Immunology
Chronic liver disease
Cardiology
Disease
Pembrolizumab
Biochemistry
Chemistry
Decompensation
Hazard ratio